Insights from a Survey of Drug Formulation Experts: Challenges and Preferences in High-Concentration Subcutaneous Biologic Drug Development

药物输送 药品 医学 药物开发 临床试验 药理学 新产品开发 制药工业 重症监护医学 风险分析(工程) 生物制剂 剂型 药物制剂 活性成分 仿制药 药学 输送系统 产品(数学) 立即释放 靶向给药
作者
Mehul G. Desai,Amitava Kundu,Michael J. Hageman,Hao Lou,Srini N. Tenjarla,Changquan Calvin Sun,Feng Zhang,Omar Rahman
出处
期刊:Aaps Journal [Springer Science+Business Media]
卷期号:27 (6): 142-142 被引量:11
标识
DOI:10.1208/s12248-025-01132-8
摘要

Increasing the concentration of intravenous (IV) biologic formulations to render them appropriate for subcutaneous (SC) delivery is challenging because it impacts many interrelated variables, including volume, viscosity, and stability. This study gathered drug formulation expert insights regarding these challenges as well as development approach preferences and perceptions concerning formulation volume. Biotechnology and pharmaceutical industry experts familiar with creating high-concentration (≥ 100 mg/mL) biologic drug formulations for SC delivery completed an online survey between 26 April and 7 May 2024. In total, there were 100 respondents included. When asked to rank seven approaches to transitioning a formulation from IV to SC administration, responses showed that increasing drug concentrations to reduce injection volume and/or changing the primary container were considered riskier, more time-consuming, and more costly than maintaining the concentration and using an on-body delivery system (OBDS). The greatest challenges mentioned were solubility issues (75%), viscosity-related challenges (72%), and aggregation issues (68%). Most respondents (69%) reported delays in clinical trials or product launches due to high-concentration SC formulation challenges. Of these, 33.3% experienced delays of 6-9 months (weighted mean: 11.3 months), while 4.3% indicated that trials or launches were canceled entirely due to formulation difficulties. In conclusion, making minimal drug formulation concentration changes to an IV biologic formulation may reduce the risk, time commitment, and cost associated with developing a SC biologic formulation. Further education is needed around the transition of traditional IV formulations to low-concentration, large-volume SC formulations utilizing delivery formats such as an SC infusion pump or OBDS.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zk001完成签到,获得积分10
刚刚
芦苇完成签到 ,获得积分10
刚刚
1秒前
拽根大恐龙完成签到,获得积分10
1秒前
言小言发布了新的文献求助10
1秒前
chenguanyiren完成签到 ,获得积分10
1秒前
求助文献完成签到,获得积分10
1秒前
able0812完成签到,获得积分10
1秒前
科研民工完成签到,获得积分10
2秒前
Michael_li发布了新的文献求助10
2秒前
氧硫硒锑铋完成签到,获得积分10
2秒前
小繁发布了新的文献求助10
2秒前
JoJoT完成签到,获得积分10
2秒前
香蕉觅云的应助被poi采纳,获得10
3秒前
Polaris完成签到 ,获得积分10
3秒前
黄小保完成签到,获得积分10
3秒前
熊火焰完成签到,获得积分10
4秒前
忧郁觅山发布了新的文献求助10
4秒前
阳光依波完成签到,获得积分20
4秒前
jinyu完成签到,获得积分10
4秒前
zxy完成签到,获得积分10
4秒前
可靠的怜珊完成签到 ,获得积分10
4秒前
wwdd完成签到,获得积分10
4秒前
bkagyin的应助被galioo3000采纳,获得10
4秒前
顾矜的应助被nicolas采纳,获得10
5秒前
可爱的函函的应助被able0812采纳,获得10
5秒前
zdw完成签到,获得积分10
5秒前
最好的发布了新的文献求助10
5秒前
zhengzhao完成签到,获得积分10
5秒前
谢小胖完成签到,获得积分10
5秒前
失眠的英姑完成签到,获得积分10
6秒前
吕奎完成签到,获得积分10
6秒前
TQ完成签到,获得积分10
6秒前
2275523154完成签到,获得积分10
6秒前
窦函完成签到,获得积分10
7秒前
怡然的飞珍完成签到,获得积分10
7秒前
7秒前
CodeCraft的应助被糊涂的砖头采纳,获得10
7秒前
淡然宛凝完成签到 ,获得积分10
7秒前
加油完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180189
求助须知:如何正确求助?哪些是违规求助? 9570320
关于积分的说明 21810161
捐赠科研通 7776320
什么是DOI,文献DOI怎么找? 3433267
关于科研通互助平台的介绍 2557483
邀请新用户注册赠送积分活动 2479039